Document Detail


Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
MedLine Citation:
PMID:  19901096     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To identify factors associated with virological response (VR) to an etravirine (ETR)-based regimen, 243 patients previously treated with nonnucleoside reverse transcriptase inhibitors (NNRTIs) were studied. The impact of baseline HIV-1 RNA, CD4 cell count, past NNRTIs used, 57 NNRTI resistance mutations, genotypic sensitivity score (GSS) for nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), and the number of new drugs used with ETR for the first time on the VR to an ETR regimen were investigated. Among the 243 patients, the median baseline HIV-1 RNA level was 4.4 log(10) copies/ml (interquartile range [IQR], 3.7 to 4.9) and the median CD4 count was 175 cells/mm(3) (IQR, 69 to 312). Patients had been previously exposed to a median of 6 NRTIs, 1, NNRTI, and 5 PIs. Overall, 82% of patients achieved a VR at month 2, as defined by a decrease of at least 1.5 log(10) copies/ml and/or HIV-1 RNA level of <50 copies/ml. No difference in VR was observed between patients receiving or not a boosted PI in combination with ETR. Factors independently associated with a better VR to ETR were the number of drugs (among enfuvirtide, darunavir, or raltegravir) used for the first time in combination with ETR and the presence of the K103N mutation at baseline. Mutations Y181V and E138A were independently associated with poor VR, whereas no effect of the Y181C on VR was observed. In conclusion, ETR was associated with high response rates in NNRTI-experienced patients in combination with other active drugs regardless of the therapeutic class used.
Authors:
Anne-Genevieve Marcelin; Philippe Flandre; Diane Descamps; Laurence Morand-Joubert; Charlotte Charpentier; Jacques Izopet; Mary-Anne Trabaud; Henia Saoudin; Constance Delaugerre; Catherine Tamalet; Jacqueline Cottalorda; Magali Bouvier-Alias; Dominique Bettinger; Georges Dos Santos; Annick Ruffault; Chakib Alloui; Cecile Henquell; Sylvie Rogez; Francis Barin; Anne Signori-Schmuck; Sophie Vallet; Bernard Masquelier; Vincent Calvez;
Related Documents :
21344966 - Circumferential encasement of the spinal cord in a patient with rheumatoid arthritis.
21442166 - Subclinical atherosclerosis in gouty arthritis patients: a comparative study.
11673296 - Plasma homocysteine, methylene tetrahydrofolate reductase c677t and factor ii g20210a p...
20671416 - Resistin level is positively correlated with thrombotic complications in southern chine...
12038516 - Upper and lower gastrointestinal endoscopical investigation in elderly patients with ir...
11373456 - Increased incidence of sepsis and altered monocyte functions in severely injured type a...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-11-09
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  54     ISSN:  1098-6596     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-21     Completed Date:  2010-03-15     Revised Date:  2013-08-26    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  72-7     Citation Subset:  IM    
Affiliation:
Department of Virology, Pitié-Salpêtrière Hospital, 83 Boulevard de l'Hôpital, 75013 Paris, France. anne-genevieve.marcelin@psl.aphp.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-HIV Agents / therapeutic use*
Drug Resistance, Viral / genetics
Female
Genotype
HIV Infections / drug therapy*,  virology*
HIV Reverse Transcriptase / genetics
HIV-1* / drug effects,  genetics
Humans
Male
Mutation
Phylogeny
Pyridazines / therapeutic use*
RNA, Viral / biosynthesis,  genetics
Reverse Transcriptase Inhibitors / therapeutic use*
Reverse Transcriptase Polymerase Chain Reaction
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Pyridazines; 0/RNA, Viral; 0/Reverse Transcriptase Inhibitors; 0C50HW4FO1/etravirine; EC 2.7.7.49/HIV Reverse Transcriptase
Investigator
Investigator/Affiliation:
C Alloui / ; D Bettinger / ; G Anies / ; B Masquelier / ; S Vallet / ; C Henquell / ; M Bouvier-Alias / ; G Dos Santos / ; A Signori-Schmuck / ; S Rogez / ; P Andre / ; J C Tardy / ; M A Trabaud / ; C Tamalet / ; B Montes / ; J Cottalorda / ; D Descamps / ; F Brun-Vézinet / ; C Charpentier / ; M L Chaix / ; S Fourati / ; A G Marcelin / ; V Calvez / ; P Flandre / ; L Morand-Joubert / ; C Delaugerre / ; A Ruffault / ; A Maillard / ; T Bourlet / ; H Saoudin / ; J Izopet / ; F Barin / ; O Bouchaud / ; B Hoen / ; M Dupon / ; P Morlat / ; D Neau / ; M Garré / ; V Bellein / ; C Jacomet / ; Y Lévy / ; S Dominguez / ; A Cabié / ; P Leclercq / ; P Weinbreck / ; L Cotte / ; I Poizot-Martin / ; I Ravaud / ; J Reynes / ; P Dellamonica / ; P Yeni / ; R Landman / ; L Weiss / ; C Piketty / ; J P Viard / ; C Katlama / ; A Simon / ; P M Girard / ; J L Meynard / ; J M Molina / ; M T Goeger-Sow / ; I Lamaury / ; C Michelet / ; F Lucht / ; B Marchou / ; P Massip / ; J M Besnier /
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of Y143 HIV-1 integrase mutations on resistance to Raltegravir in vitro and in vivo.
Next Document:  Is It Time to Eliminate Consultation Codes?: An Analysis of Impact and Rationale.